Why the study?
Does BMS-180448 reduce infarct size without causing hypotension in animal models of myocardial ischemia?
Does BMS-180448 reduce infarct size without causing hypotension in animal models of myocardial ischemia?
BMS-180448 is a cardiac-selective KATP opener that provides cardioprotection against ischemia-reperfusion injury without the hypotensive side effects seen with non-selective agents.
No takes yet. Share an insight, caveat, or question.
Animal data suggest selective KATP activation limits infarct size without hypotension; leaves open translation to clinical reperfusion injury.
Grover et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: